Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dexamethasone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    847 result(s) found for: Dexamethasone. Displaying page 8 of 43.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2017-003189-29 Sponsor Protocol Number: ONCO-01-2017 Start Date*: 2018-02-09
    Sponsor Name:L'Institut Mutualiste Montsouris
    Full Title: A phase II/III multicentric randomized trial, compared abiraterone + dexamethasone versus standard abiraterone + prednisone in patients resistant-castration in metastatic prostate cancer
    Medical condition: Metastatic castration resistant prostate cancer patients under abiraterone + prednisone with exclusive biological progression (PSA progression on the PSAWG3 criteria)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003001-85 Sponsor Protocol Number: BDD Start Date*: 2005-11-28
    Sponsor Name:Austrian Forum against Cancer
    Full Title: Bortezomib-Doxorubicin-Dexamethasone (BDD) as Treatment for Patients with Multiple Myeloma Presenting with Acute Renal Failure
    Medical condition: The occurrence of renal failure is an emergency situation in patients with multiple myeloma. A fast active relatively, non-toxic protocol seems presently the best option for attempts to reverse ren...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2020-006054-43 Sponsor Protocol Number: MEDEAS Start Date*: 2021-03-03
    Sponsor Name:Università degli Studi di Trieste
    Full Title: Randomized controlled trial of methylprednisolone versus dexamethasone in COVID-19 pneumonia
    Medical condition: Hospitalized patients with COVID-19 requiring respiratory support
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000402-30 Sponsor Protocol Number: SO_SH_01_2019 Start Date*: 2019-04-10
    Sponsor Name:Viktoria Lindberg-Larsen
    Full Title: The effect of perioperative dexamethasone administration on postoperative pain in patients undergoing periacetabular osteotomy: A randomised double-blind, placebo-controlled trial
    Medical condition: Dysplasia of the hip
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10063175 Hip dysplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002771-10 Sponsor Protocol Number: MP0250-CP201 Start Date*: 2017-03-27
    Sponsor Name:Molecular Partners AG
    Full Title: A Phase II open-label, single-arm, multicenter trial of MP0250 plus bortezomib+dexamethasone in patients with refractory and relapsed multiple myeloma
    Medical condition: Multiple myeloma (MM) is a relatively rare (114 000 new cases worldwide in 2012, i.e. 0.8% of total cancer cases [Cancer Research UK Incidence Statistics 2016]) blood cancer for which there is no c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) DK (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-000388-28 Sponsor Protocol Number: 00658;MK-0683-201 Start Date*: 2011-06-30
    Sponsor Name:University Medical Center Freiburg
    Full Title: Safety of Vorinostat in combination with Bortezomib, Doxorubicin and Dexamethasone (VBDD) in patients with refractory or relapsed multiple myeloma
    Medical condition: Relapsed or refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001330-29 Sponsor Protocol Number: LENALID01 Start Date*: 2015-01-30
    Sponsor Name:Ernesto Pérez Persona
    Full Title: No
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000268-17 Sponsor Protocol Number: CC-4047-MM-007 Start Date*: 2015-04-02
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE VERSUS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJEC...
    Medical condition: relapsed or refractory multiple myeloma (MM)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) NO (Completed) DK (Completed) SE (Completed) FI (Completed) ES (Completed) PT (Completed) AT (Completed) PL (Completed) GR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004767-31 Sponsor Protocol Number: CC-92480-MM-002 Start Date*: 2019-12-02
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Su...
    Medical condition: Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM (NDMM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) CZ (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001020-38 Sponsor Protocol Number: CRFB002EDE18 Start Date*: 2011-06-24
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal imp...
    Medical condition: visual impairment due to macular edema following central retinal vein occlusion (CRVO)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002711-94 Sponsor Protocol Number: HO124WM Start Date*: 2014-09-19
    Sponsor Name:HOVON Foundation
    Full Title: HOVON 124 WM study: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenström's macroglobulinemia.
    Medical condition: Waldenström's macroglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10054697 Waldenstrom's macroglobulinemia recurrent LLT
    21.1 100000004864 10054698 Waldenstrom's macroglobulinemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004823-39 Sponsor Protocol Number: CC-5013-MM-020/IFM 07-01 Start Date*: 2008-04-03
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, 3-ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) PLUS LOW-DOSE DEXAMETHASONE WHEN GIVEN UNTIL PROGRESSIVE DISEASE OR FOR 18 FOUR-WEEK...
    Medical condition: Previously untreated multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) IE (Prematurely Ended) IT (Completed) AT (Completed) ES (Completed) SE (Completed) BE (Completed) PT (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000803-20 Sponsor Protocol Number: C1071006 Start Date*: 2022-11-02
    Sponsor Name:Pfizer Inc.
    Full Title: MAGNETISMM-6: AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENA...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) ES (Restarted) CZ (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) HU (Prematurely Ended) FR (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) AT (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002191-25 Sponsor Protocol Number: PCYC-1138-CA Start Date*: 2016-03-31
    Sponsor Name:Pharmacyclics LLC
    Full Title: A Randomized Multicenter Study of Ibrutinib in Combination with Pomalidomide and Dexamethasone in Subjects with Relapsed/Refractory Multiple Myeloma
    Medical condition: Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-003430-13 Sponsor Protocol Number: AALL0932 Start Date*: 2014-01-14
    Sponsor Name:Children's Oncology Group
    Full Title: Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)
    Medical condition: Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    20.0 100000004864 10003939 B-lymphoblastic lymphoma (Kiel Classification) LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-006677-83 Sponsor Protocol Number: HuLuc63-1703 Start Date*: 2010-04-26
    Sponsor Name:AbbVie Biotherapeutics Inc. (AbbVie)
    Full Title: A Phase 1b/II, Multicenter, Open-Label, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination with Lenalidomide and Dexamethasone in Subjects with Relapse...
    Medical condition: Patients with relapsed multiple myeloma (MM).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000202-22 Sponsor Protocol Number: 64407564MMY3002 Start Date*: 2023-01-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002767-30 Sponsor Protocol Number: ACT17453 Start Date*: 2023-02-23
    Sponsor Name:Sanofi-aventis recherche & developpement
    Full Title: A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory ...
    Medical condition: Relapsed/refractory multiple myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004864 10086466 Relapsed/refractory multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001261-33 Sponsor Protocol Number: Start Date*: 2019-11-05
    Sponsor Name:University College London
    Full Title: Randomised phase II/III study of Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as initial therapy for Waldenström's macroglobulinaemia
    Medical condition: Waldenström's macroglobulinaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-001628-35 Sponsor Protocol Number: X05140 Start Date*: 2006-01-31
    Sponsor Name:EBMT - CLWP
    Full Title: A randomized controlled study of Velcade (Bortezomib) plus Thalidomide plus Dexamethasone compared to Thalidomide plus Dexamethasone for the treatment of myeloma patients progressing or relapsing a...
    Medical condition: multiple myeloma patients in progression or relapse after autologous transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) CZ (Completed) AT (Completed) HU (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 12:39:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA